GLOW (70 mg)

Overview

• Composition: GHK-Cu 50 mg + TB-500 10 mg + BPC-157 10 mg (5:1:1 ratio) in a 70 mg lyophilised vial.
• Goal: Comprehensive tissue repair combining GHK-Cu’s genomic repair foundation with TB-500’s systemic reach and BPC-157’s local healing.^[1][2]
• Schedule: Once-daily SC injection for a 4-week cycle; 2–4 weeks off.
• Reconstitution: 3.0 mL BAC water per 70 mg vial → 23.3 mg/mL.
• Storage: Lyophilised at −20 °C; reconstituted at 2–8 °C; use within 4 weeks.

What You’ll Need

Plan based on a 4-week cycle at 2,330 mcg once daily (28 injections, ~65.2 mg total).

• GLOW Vials (70 mg each): ~65.2 mg needed ÷ 70 mg per vial → 1 vial (with ~2 injections to spare).
• Insulin Syringes (U-100, 0.3 mL / 30-unit): 28 injections → 28 syringes.
• Bacteriostatic Water (10 mL bottles): 3.0 mL per vial → 1 × 10 mL bottle.
• Alcohol Swabs: 2 per injection → 56 swabs per 4-week cycle.

How to Reconstitute

1. Allow frozen lyophilised vial to reach room temperature (10–15 minutes).
2. Draw 3.0 mL bacteriostatic water with a sterile syringe.
3. Inject slowly down the inner vial wall to avoid foaming.
4. Gently swirl until fully dissolved — do not shake. Solution will have a characteristic blue colour from GHK-Cu’s copper chelation; this is normal.
5. Label with reconstitution date; refrigerate at 2–8 °C, protected from light. Use within 4 weeks.

Dosing Schedule

Begin at 1,165 mcg once daily for the first 2 weeks to assess tolerability, then advance to 2,330 mcg for weeks 3–4. The 5:1:1 ratio prioritises GHK-Cu’s broad genomic repair while TB-500 and BPC-157 contribute systemic and local repair. For injuries with a strong local component, inject subcutaneously near the injury site to enhance BPC-157’s local FAK-paxillin effects.

Vial duration: At the standard 2,330 mcg/day dose, each 70 mg vial provides 30 injections (0.10 mL each from 3.0 mL total) — enough for a full 4-week cycle.

Protocol Details

• Weeks 1–2 (starting): 1,165 mcg (5 units / 0.05 mL) once daily — half-dose tolerability phase.^[2]
• Weeks 3–4 (standard): 2,330 mcg (10 units / 0.10 mL) once daily.
• Each standard injection delivers: ~1,664 mcg GHK-Cu + ~333 mcg TB-500 + ~333 mcg BPC-157.
• Injection site: Abdomen, thigh, or upper arm (rotate daily). For injuries with a strong local component, proximity to injury site enhances BPC-157’s local effects.

Storage

• Lyophilised: Store at −20 °C (−4 °F) or below; protect from moisture and light.
• Reconstituted: Refrigerate at 2–8 °C. Do not freeze. Use within 4 weeks.
• Blue colour: GHK-Cu copper chelation gives the solution a characteristic blue colour — inspect for clarity but do not expect the colourless appearance of other peptides.

How GLOW Works

GLOW combines three peptides into a single coordinated repair protocol:

• GHK-Cu (50 mg — primary component): Copper tripeptide that modulates 4,000+ repair genes, stimulates collagen synthesis (types I, III, IV), balances MMPs/TIMPs, and delivers bioavailable copper to cuproenzymes (lysyl oxidase, SOD1).^[1]
• TB-500 (10 mg): Binds G-actin for systemic cell migration, angiogenesis, anti-inflammatory, and anti-fibrotic signalling body-wide.
• BPC-157 (10 mg): Drives local repair via FAK-paxillin pathway, VEGF upregulation, and NO-pathway normalisation.^[2]

The 5:1:1 ratio prioritises GHK-Cu’s broad genomic repair foundation while TB-500 and BPC-157 contribute systemic and local repair mechanisms respectively.

Good to Know

• GLOW solution is normally blue — this is expected and indicates intact GHK-Cu copper chelation. Do not discard on this basis alone.
• GLOW is the core regeneration blend; for contexts involving gut inflammation or immune modulation, consider the KLOW blend which adds KPV for mucosal protection.
• WADA-prohibited — TB-500 and BPC-157 are Category S2 non-approved peptides. Athletes under anti-doping rules must not use GLOW.
• Rotate injection sites daily; document dose, site, and any local reactions.
• Genomic repair: GHK-Cu modulates 4,000+ genes; 31/66 chronic disease genes shifted toward healthy phenotypes.^[1]
• Musculoskeletal repair: BPC-157 and TB-500 components provide local and systemic tissue repair — same evidence base as the Wolverine Stack.^[2]
• Skin and connective tissue: GHK-Cu’s collagen synthesis and matrix remodelling make GLOW particularly suited to skin, joint, and connective tissue recovery contexts.
• Blue solution: GHK-Cu’s copper chelation produces a characteristic blue colour — document this in protocol notes to avoid confusion.
• WADA status: TB-500 and BPC-157 components are prohibited; GHK-Cu has no explicit WADA prohibition as of 2025 but GLOW as a blend is non-approved.

Tips for Best Results

• Maintain adequate dietary protein (1.2–1.6 g/kg) and vitamin C (collagen cofactor) for GHK-Cu’s collagen synthesis effects.
• Protect skin from UV exposure during GLOW cycles — new matrix formation increases photosensitivity.
• Avoid NSAIDs during GLOW cycles — they counteract BPC-157’s NO-pathway and VEGF repair signalling.

Injection Tips

• Clean the vial stopper and injection site with separate alcohol swabs; allow both to air-dry fully before proceeding.
• Using a 29–31 gauge insulin syringe (5/16″ to 1/2″ needle), draw the calculated dose precisely.
• Pinch a fold of skin and insert the needle at 45° into subcutaneous fat (90° is acceptable with a short needle into a well-pinched fold).
• Inject slowly over 2–3 seconds; do not aspirate. Withdraw the needle, apply gentle pressure, and do not rub the site.
• Rotate injection sites (abdomen, thighs, upper arms) and dispose of each syringe in a sharps container immediately after use.

Related Reading

Learn more about the peptides in this protocol:

• What Is the GLOW Peptide Blend?
• What Is GHK-Cu?
• What Is BPC-157?
• What Is TB-500?
• Peptide Dosage Calculator